

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-17. (Canceled)

18. (Currently Amended) A method for inhibiting or suppressing viral replication in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies.

19. (Currently Amended) A method for inhibiting or suppressing viral replication in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more viral antigens.

20. (Canceled)

21. (Currently Amended) A method for inhibiting or suppressing microbial replication in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies.

22. (Currently Amended) A method for inhibiting or suppressing microbial replication in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for one or more microbial antigens.

23. (Canceled)

24. (Previously Presented) The method of claim 18, 19, 21 or 22 further comprising administering to the animal IgG enriched plasma.

25. (Previously Presented) The method of claim 18, 19, 21 or 22 further comprising administering to the animal IgM enriched plasma.

26. (Previously Presented) The method of claim 24 further comprising administering to the animal IgM enriched plasma.

27. (Previously Presented) The method of claim 18, 19, 21 or 22 further comprising administering to the animal one or more complement components.

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Currently Amended) A method for treating septic shock in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of one or more anti-C3b(i) antibodies.

33. (Previously Presented) The method of claim 18, 19, 21, 22 or 32, wherein at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for (i) C3b(i) and (ii) an effector cell receptor or antigen.

34. (Previously Presented) The method of claim 18, 19, 21, 22 or 32, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody.

35. (Previously Presented) The method of claim 34, wherein the monoclonal antibody is a human or humanized antibody.

36. (Previously Presented) The method of claim 33 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer or erythrocyte.

37. (Previously Presented) The method of claim 33 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64 or CD89.

38. (Previously Presented) The method of claim 18, 19, 21, 22 or 32 in which at least one of anti-C3b(i) antibodies is conjugated to a therapeutic agent.

39. (Currently Amended) The method of claim 18, 19, ~~20~~, 21, 22, ~~23~~ or 32 in which the animal is a mammal.

40. (Currently Amended) The method of claim 18, 19, ~~20~~, 21, 22, ~~23~~ or 32 in which the animal is a human.

41. (Currently Amended) The method of claim 18, or 19 ~~or 20~~, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to an IgM antibody or an IgG antibody, which IgM antibody or IgG antibody is bound to a virus.

42. (Currently Amended) The method of claim 18, or 19 ~~or 20~~, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to a viral antigen.

43. (Currently Amended) The method of claim 21, or 22 ~~or 23~~, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to an IgM antibody or an IgG antibody, which IgM antibody or IgG antibody is bound to a microbe.

44. (Currently Amended) The method of claim 21, or 22 ~~or 23~~, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to a microbial antigen.

45. (Previously Presented) The method of claim 32, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to lipopolysaccharide.

46. (Currently Amended) The method of claim 42 in which ~~at least one of the viral antigens~~ antigen is HIV gp120 or RSV F glycoprotein.

47. (Currently Amended) The method of claim 44 in which ~~at least one of the microbial antigens~~ antigen is lipopolysaccharide.

48. (Currently Amended) The method of claim 18, or 19 ~~or 20~~ in which the virus ~~is viral infection is caused by~~ a retrovirus, a herpes virus, an arenavirus, a paramyxovirus, an adenovirus, a bunyavirus, a ~~coronavirus~~ coronavirus, a filovirus, a flavivirus, a hepadnavirus,

an ~~orthomyxovirus~~ orthomyxovirus, a papovavirus, a picornavirus, a poxvirus, a reovirus, a togavirus, or a rhabdovirus.

49. (Currently Amended) The method of claim 21, ~~or 22 or 23~~ in which the ~~microbial infection~~ microbe is a yeast ~~infection~~, fungal ~~infection~~ fungus, protozoan ~~infection~~ or bacterial ~~infection~~ bacterium.

50. (Currently Amended) The method of claim 49 in which the bacterium is ~~bacterial infection is caused by~~ *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter* (*Vibrio*) *fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis* *pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema pertenue*, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma* spp., *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia* spp., or *Helicobacter pylori*. ~~*Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Treponema pallidum*, *Treponema pertenue*, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma* spp., *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia* spp., or *Helicobacter pylori*.~~

51. (New) A method for inhibiting or suppressing viral replication in an animal in need thereof, said method comprising administering to the animal a therapeutically effective amount of a bispecific antibody which is immunospecific for (i) C3b(i) and (ii) an effector cell receptor or antigen.

52. (New) The method of claim 51 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer or erythrocyte.

53. (New) The method of claim 51 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64 or CD89.

54. (New) The method of claim 51 further comprising administering to the animal IgG enriched plasma.

55. (New) The method of claim 51 further comprising administering to the animal IgM enriched plasma.

56. (New) The method of claim 51 further comprising administering to the animal one or more complement components.

57. (New) The method of claim 51 in which the animal is a mammal.

58. (New) The method of claim 51 in which the animal is a human.

59. (New) The method of claim 51, wherein the bispecific antibody is immunospecific for (i) C3b(i) linked to an IgM antibody or IgG antibody, which IgM antibody or IgG antibody is bound to a virus, and (ii) an effector cell receptor or antigen.

60. (New) The method of claim 51, wherein the bispecific antibody is immunospecific for (i) C3b(i) linked to a viral antigen and (ii) an effector cell receptor or antigen.

61. (New) The method of claim 51 in which the virus is a retrovirus, a herpes virus, an arenavirus, a paramyxovirus, an adenovirus, a bunyavirus, a coronavirus, a filovirus, a flavivirus, a hepadnavirus, an orthomyxovirus, a papovavirus, a picornavirus, a poxvirus, a reovirus, a togavirus, or a rhabdovirus.

62. (New) The method of claim 18, 19, 21, 22, 32 or 51 in which said anti-C3b(i) antibodies are specific for the C3b(i) fragment.